HCI-024 breast cancer PDX
HCI-024 PDX: One of many Patient Derived Xenografts providing breast cancer models including endocrine-resistant estrogen receptor-positive (ER+).
Contributors
| Inventor | Institute |
|---|---|
| Alana L Welm, Yi-Chun Lin, Yoko Sakata DeRose | The University of Utah Research Foundation |
| Cat. #: | 162090 |
|---|---|
| Cancer types: | Breast cancer |
| Cancer Subtype: | Infiltrating Ductal Carcinoma |
| Gender: | Female |
| Biopsy Site: | Skin metastasis |
| Patient ethnicity: | Caucasian |
| Treatment History: | Pretreated: Patient had not undergone radiation therapy but received systemic treatment of doxorubicin, cyclophosphamide, and paclitaxel 2014-2015 prior to sample collection |
| Primary citation: | Guillen, et al. 2022. Nature Cancer. Feb; 3(2):232-250. PMID: 35221336 |
| Product description: | Human breast cancer patient-derived xenograft (PDX) model that retains high fidelity to original tumour, including spatial structure, intratumour heterogeneity, genomic features, tumour growth rate, metastatic patterns, and drug responses. These highly translatable PDX models can be used to more accurately assess therapeutic efficacy and predict patient responses in preclinical drug validation studies than traditional models. This panel of PDX models includes some of the deadliest forms of breast cancer such as drug-resistant, metastatic tumours, and endocrine-resistant estrogen receptor-positive (ER+) and human epidermal growth factor receptor positive (HER2+) tumours. Sample collected in 2014 from skin metastasis of Caucasian female, age 54 at time of collection with a primary diagnosis of IDC; 2014. Patient had no prior history of smoking, and had clinical metastasis detected in brain, lung, and bone. Patient had not undergone radiation therapy but received systemic treatment of doxorubicin, cyclophosphamide, and paclitaxel 2014-2015 prior to sample collection. Patient and PDX characteristics were as follows – ER status: negative, PR status: negative, HER2 status: negative. PDX information: PAM50 subtype is basal-like and metastasis in lymph node and lung detected. |
|---|
| Initial handling information: | Implant into the cleared inguinal mammary fat pad of female Immune-compromised mice NSG. NSG (fresh) time to growth: 8 months to 2 cm. |
|---|---|
| Additional notes: | Additional Information on PDX establishment: https://www.nature.com/articles/s43018-022-00337-6/figures/9 |
| Mice Passaged: | Yes |
|---|---|
| Engraftment Site: | Cleared mammary fat pad |
| Host Strain: | Immunocompromised mice NOD scid gamma (NSG) Jackson Laboratory 5557; NOD/scid, Jackson Laboratory 1303 or NOD rag gamma (NRG), Jackson Laboratory 7799 |
| Histology: | PAM50 subtype Basal-like |
| Production details: | Fresh or thawed human breast tumour fragments were implanted into the cleared inguinal mammary fat pad of female Immune-compromised mice. For bone metastasis samples, bone fragments were coimplanted. For liquid specimens, pleural effusion, or ascites fluid, 1-2 milion cells were injected into cleared mammary fat pads in Matrigel. For ER+ tumours, mice were dosed with E2 beeswax pellets and given supplemental E2 via drinking water. When tumours reached 1-2 cm in diameter, tumours were aseptically collected and reimplanted into new m ice or banked. Estrogen-independent ER+ breast PDX models were generated when ER+ PDX tumours were transplated into overiectomized mice without E2 supplementation. |
| References: |
Tufail, et al. 2024. Journal of Translational Med. Jan 3:22(1):15. PMID: 38172946 Bhattacharya, et al. 2023. Journal of Experimental & Clinical Cancer Research. Dec 16:42(1):343. PMID: 38102637 Prekovic, et al. 2023. EMBO Molecular Medicine. Dec 7:15(12):e17737. PMID: 37902007 Daneshdoust, et al. 2023. Cells. Sep 30:12(19):2338. PMID: 37830602 Wang, et al. 2023. Cell Bioscience. Dec 1:13(1):224. PMID: 38041134 Guillen, et al. 2022. Nature Cancer. Feb 3(2):232-250. PMID: 35221336 |
|---|
Related Tools for PDX models
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 152089 | MCF7/TAMR-1 Cell Line |
Key Info
MCF7/TAMR-1 Cell Line
|
View Tool | |||||||||||||||||||
| 152090 | MCF7/S0.5 Cell Line |
Key Info
MCF7/S0.5 Cell Line
|
View Tool | |||||||||||||||||||
| 152698 | Anti-PALB2 [M41-P3F3] |
Key Info
Anti-PALB2 [M41-P3F3]
|
View Tool | |||||||||||||||||||
| 161584 | Anti-Maspin [16F7] |
Key Info
Anti-Maspin [16F7]
|
View Tool | |||||||||||||||||||
| 162075 | HCI-007 breast cancer PDX | View Tool | ||||||||||||||||||||
